A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers

Aflah Roohullah, Adam Cooper, Anna J. Lomax, Jennifer Aung, Alan Barge, Lilian Chow, Mark McHale, Jayesh Desai, James R. Whittle, Ben Tran, Paul de Souza, Lisa G. Horvath

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science